Source: Eur Respir J 2013; 41: 18-24
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Hooper Clare E., Morley Anna J., Virgo Paul, Harvey John E., Kahan Brennan, Maskell Nick A.. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J 2013; 41: 18-24

Member's Comments

No comment yet.

Related content which might interest you: Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Is pleural VEGF a useful parameter? Source: Annual Congress 2007 - Pleural malignancy Year: 2007 Epidemiology, etiology, prognosis and presentation of malignant pleural mesothelioma Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 The value of adenosin-deaminase in etiologic diagnosis of pleural effusions Source: Eur Respir J 2002; 20: Suppl. 38, 167s Year: 2002 Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Source: Eur Respir Rev 2016; 25: 472-486 Year: 2016 Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion? Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019 Sonographic echogenic swirling pattern in patients with malignancies: a useful diagnostic predictor for malignant pleural effusions Source: Annual Congress 2008 - Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases Year: 2008 Utility of pleural fluid for predictive marker testing in malignant pleural effusion Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020 Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Clinical usefulness of the novel drug sensitivity test for malignancy using pleural effusion Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity Year: 2006 The role of diagnostic thoracoscopy in patients with lung cancer and pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 542s Year: 2003